Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Abbott Laboratories (NYSE: ABT ) stock is down almost 8% since the end of May. Is now a good time to buy? Let's take a look.
Anatomy of a pullback
There's no question that Abbott started 2013 with a bang. The year began with the spinoff of AbbVie (NYSE: ABBV ) . By the latter part of May, shares were up more than 20%. Then came the slide.
What happened? Although the company announced first-quarter results just days before the decline, those results weren't at fault. Abbott reported solid if not spectacular numbers for the period.
Instead, a primary culprit in this case appears to be the drag of the overall market. The S&P 500 index is down 4% since late May. Abbott's drop has been larger, but there haven't been any negatives specific to the company that appear to have contributed to the decline.
We could look at several aspects of Abbott Laboratories stock and conclude that now is definitely a great time to buy. The trailing price-to-earnings multiple of below 11 seems to be attractive. Abbott boasts a return on equity of more than 25%, a number nearly any company would be happy to claim.
It might be beneficial to examine things a little more closely, though. That P/E multiple just shy of 11 actually is near the highest level over the past five years. And most of those five years included the growth engine of Humira, which now solely belongs to AbbVie and not Abbott.
Abbott's dividend yield isn't nearly as appealing as its spin-off, either. AbbVie sports a forward yield of 3.7%. Abbott Laboratories stock yields only 1.5%.
The one company that probably compares best with Abbott in terms of business models also looks like a more compelling buy. Johnson & Johnson (NYSE: JNJ ) is up nearly 17% year to date -- much better performance than Abbott Labs. J&J's dividend yield of 3.1% also ranks higher.
On the other hand, J&J's stock is valued more highly than Abbott's -- with a trailing P/E of nearly 23. J&J also doesn't stack up as well on another important metric. Its return on equity of 15.76% stands well below that of Abbott.
My view not long ago was that Abbott was a decent stock pick. I haven't changed that opinion.
The company's nutrition products group continues to perform well. Emerging markets, in particular, hold a lot of promise. If Abbott could get its established pharmaceuticals and medical-devices segments firing on all cylinders, it should really do well.
The recent pullback presents a positive in that Abbott Laboratories stock is even more attractively valued. However, because much of the decline is due to the overall market climate, continued macro concerns could bring shares down even more.
Over the long run, though, I like Abbott. Sure, there are health-care stocks that probably present better opportunities. But is now a good time to buy Abbott Laboratories stock? This Fool says "yes."
Abbott Labs has changed forever after losing its branded pharmaceutical business to a spinoff. If you're a current investor, or might be buying shares soon, make sure you truly understand the stock by reading The Motley Fool's comprehensive premium report on Abbott Labs. The report outlines all of the must-know opportunities and risks, along with a full year of analyst updates to keep you up to speed. Best of all, you can claim this report today by clicking here now.